Dianthus Therapeutics, Inc. /DE/ — Director's Dealing 2019

Jan 4, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Magenta Therapeutics, Inc. (MGTA)
CIK: 0001690585
Period of Report: 2019-01-02

Reporting Person: Ryan Jason (See Remarks)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-02	Stock Option (Right to Buy)	$6.00	A	329379	Acquired	2029-01-01	Common Stock (329379)	Direct

Footnotes

F1: This option shall vest and become exerciseable over four years, with 25% of this option vesting on January 1, 2020, and the remainder vesting in 36 equal monthly installments thereafter.